SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AS A PROGNOSTIC FACTOR IN BLADDER CANCER
2001; Lippincott Williams & Wilkins; Volume: 166; Issue: 4 Linguagem: Inglês
10.1016/s0022-5347(05)65752-7
ISSN1527-3792
AutoresS. Bernardini, Sylvie Fauconnet, É. Chabannes, Pierre-Charles Henry, G Adessi, Hugues Bittard,
Tópico(s)Inflammatory mediators and NSAID effects
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Oct 2001SERUM LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AS A PROGNOSTIC FACTOR IN BLADDER CANCER S. BERNARDINI, S. FAUCONNET, E. CHABANNES, P.C. HENRY, G. ADESSI, and H. BITTARD S. BERNARDINIS. BERNARDINI , S. FAUCONNETS. FAUCONNET , E. CHABANNESE. CHABANNES , P.C. HENRYP.C. HENRY , G. ADESSIG. ADESSI , and H. BITTARDH. BITTARD View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)65752-7AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Vascular endothelial growth factor is an overriding growth factor mediating tumor angiogenesis. We correlated serum vascular endothelial growth factor in patients with bladder cancer with clinical parameters. Materials and Methods: Serum vascular endothelial growth factor in 58 patients with bladder cancer, including superficial and invasive tumors in 42 and 16, respectively, and 41 healthy controls was measured by sandwich enzyme immunoassay. Results: Significant differences in serum vascular endothelial growth factor were observed in healthy controls and patients with bladder cancer (mean 248 versus 100 pg./ml., p <0.001). The serum level was significantly associated with tumor stage (p <0.0001), grade (p <0.002), vascular invasion (p <0.001) and carcinoma in situ (p <0.01). Patients with metastasis had a significantly higher levels than those with localized diseases (mean 582 versus 194 pg./ml., p <0.0001). At a cut-off of 400 pg./ml. the sensitivity and specificity of the test for differentiating patients with and without metastatic diseases was 87.5% and 98%, respectively (p <0.0001). Univariate statistical analysis showed that an increase in serum vascular endothelial growth factor level greater than 400 pg./ml. was significantly related to disease-free survival. On multivariate analysis only stage remained as an independent prognostic factor. Conclusions: Although vascular endothelial growth factor did not remain an independent prognostic factor on multivariate analysis, our data indicate that the level of vascular endothelial growth factor may be a valuable angiogenic marker for identifying metastatic bladder cancer. It may be used as a new predictor of disease. References 1 : Molecular mediators of angiogenesis in bladder cancer. Cancer Res1998; 58: 1298. Google Scholar 2 : Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res1995; 55: 510. Google Scholar 3 : Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line. J Cell Physiol1993; 155: 368. Google Scholar 4 : Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence. Cancer1999; 86: 316. Google Scholar 5 : The angiogenetic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res1996; 56: 2515. Google Scholar 6 : The vascular endothelial growth factor family identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol1991; 5: 1806. Google Scholar 7 : Differential hormonal regulation of vascular endothelial growth factors VEGF, VEGF-B, and VEGF-C messenger ribonucleic acid levels in cultured human granulosa-luteal cells. Endocrinology1997; 138: 4748. Google Scholar 8 : Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis and tumor progression. J Natl Cancer Inst1997; 89: 219. Crossref, Medline, Google Scholar 9 : Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res1997; 57: 5281. Google Scholar 10 : Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol1999; 161: 799. Link, Google Scholar 11 : Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol2000; 163: 343. Link, Google Scholar 12 : Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol1999; 74: 235. Google Scholar 13 : Elevation of serum level of vascular endothelial growth factor as a new predictor of recurrence and disease progression in patients with superficial urothelial cancer. Urology1999; 53: 302. Google Scholar 14 : Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg2000; 179: 57. Google Scholar 15 : Serum vascular endothelial growth factor is a predictor of invasion and metastasis in hepatocellular carcinoma. J Exp Clin Cancer Res1999; 18: 511. Google Scholar 16 : Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer1999; 85: 178. Google Scholar 17 : Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumors markers. Oncol Rep2000; 7: 333. Google Scholar 18 : Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res1999; 90: 874. Google Scholar 19 : Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res1998; 4: 1279. Google Scholar 20 : Serum concentrations of VEGF, b-FGF in renal cell, prostate and urinary bladder carcinomas. Anticancer Res1999; 19: 869. Google Scholar 21 : The biology of vascular endothelial growth factor. Endocr Rev1997; 10: 4. Google Scholar 22 : Release of the angiogenetic cytokine vascular endothelial growth factor from platelets: significance for VEGF measurements and cancer biology. Br J Cancer1998; 77: 956. Google Scholar 23 : Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol2000; 17: 149. Google Scholar 24 : Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res2000; 6: 3147. Google Scholar 25 : Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer2000; 82: 161. Google Scholar 26 : Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med1998; 185: 173. Google Scholar 27 : Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep2001; 8: 9. Google Scholar 28 : Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res1997; 3: 647. Google Scholar 29 : Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology1999; 54: 523. Google Scholar 30 : The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res2000; 6: 4866. Google Scholar From the Department of Urology, Centre Hospitalier Universitaire and INSERM, Besançon, France© 2001 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byReis L, Ferreira U, Billis A, Cagnon V and Fávaro W (2011) Anti-Angiogenic Effects of the Superantigen Staphylococcal Enterotoxin B and Bacillus Calmette-Guérin Immunotherapy for Nonmuscle Invasive Bladder CancerJournal of Urology, VOL. 187, NO. 2, (438-445), Online publication date: 1-Feb-2012.Shariat S, Youssef R, Gupta A, Chade D, Karakiewicz P, Isbarn H, Jeldres C, Sagalowsky A, Ashfaq R and Lotan Y (2010) Association of Angiogenesis Related Markers With Bladder Cancer Outcomes and Other Molecular MarkersJournal of Urology, VOL. 183, NO. 5, (1744-1750), Online publication date: 1-May-2010. Volume 166Issue 4October 2001Page: 1275-1279 Advertisement Copyright & Permissions© 2001 by American Urological Association, Inc.Keywordsbladder neoplasmsendothelial growth factorstumor markers, biologicalprognosisbladderMetricsAuthor Information S. BERNARDINI More articles by this author S. FAUCONNET More articles by this author E. CHABANNES More articles by this author P.C. HENRY More articles by this author G. ADESSI More articles by this author H. BITTARD More articles by this author Expand All Advertisement PDF downloadLoading ...
Referência(s)